Product Name :
D-erythro-MAPP
Description:
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro.
CAS:
143492-38-0
Molecular Weight:
361.56
Formula:
C23H39NO2
Chemical Name:
N-[(1S, 2R)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide
Smiles :
C[C@@H](NC(=O)CCCCCCCCCCCCC)[C@@H](O)C1C=CC=CC=1
InChiKey:
YLAZEWZHIRBZDA-NFBKMPQASA-N
InChi :
InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-16-19-22(25)24-20(2)23(26)21-17-14-13-15-18-21/h13-15,17-18,20,23,26H,3-12,16,19H2,1-2H3,(H,24,25)/t20-,23-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro.Fenofibrate Cytochrome P450 |Product information|CAS Number: 143492-38-0|Molecular Weight: 361.Tolfenamic Acid In Vivo 56|Formula: C23H39NO2|Chemical Name: N-[(1S, 2R)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide|Smiles: C[C@@H](NC(=O)CCCCCCCCCCCCC)[C@@H](O)C1C=CC=CC=1|InChiKey: YLAZEWZHIRBZDA-NFBKMPQASA-N|InChi: InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-16-19-22(25)24-20(2)23(26)21-17-14-13-15-18-21/h13-15,17-18,20,23,26H,3-12,16,19H2,1-2H3,(H,24,25)/t20-,23-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:31568805 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|D-erythro-MAPP (D-e-MAPP) reduces the viability of MCF-7 cells in a dose-dependent manner with IC50 value of 4.4 μM, and 15.6 μM, respectively. D-erythro-MAPP (D-e-MAPP) induces G0/G1 arrest in cell cycle progression resulting in growth suppression.|Products are for research use only. Not for human use.|